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cccodex codes. Quality of care measures included accountability measures (HbA1C
tested, foot examination and eye examination), treatmentmeasures (ACEIs/ARBs, st-
atins), health related quality of life measures (HRQoL, physical component scale- PCS
andmental component scale-MCS) and total health care expenditure. The differences
in processes of care were determined using multiple logistic regression models and
differences in the outcomes of care (HRQoL and total health care expenditure) were
examinedusingmultiple linear regressionmodels that includedbaseline socio-demo-
graphic factors, clinical factors and co-medications. RESULTS: Nearly 30% of hyper-
tensive diabetics received HbA1c test, feet examination and an eye examination at
least once a year, 61% received ACEIs/ARBs and 56% received statins. Multiple
logistic regressions found that therewere no differences in the accountabilitymea-
sures and treatment measures among patients with and without dementia. Pa-
tients with dementia had significantly lower scores on HRQoL measures (mean
PCS- 29.4 9.1 vs 37.2 12.2, p 0.001; mean MCS- 41.9 12.2 vs. 48.3 11.3, p
0.001) and more than 80% increase in total health care expenditure than patients
without dementia. CONCLUSIONS: The study found that despite the recommen-
dations by American Diabetes Association, the overall accountability measures
(HbA1C tested, foot examination and eye examination) and treatment measures
(ACEIs/ARBs, statins) were low in the elderly hypertensive diabetic patients. Al-
though the processes of care were similar, there were disparities in HRQoL and
total health care expenditures among patients with andwithout dementia indicat-
ing need of targeted efforts to improve quality of care measures in this complex
population.
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ATRIAL FIBRILLATION POPULATION IN THE UNITED STATES
Gupta S, Gross H
Kantar Health, Princeton, NJ, USA
OBJECTIVES: To determine the loss of work productivity and activity impairment
(WPAI) due to non-compliant cost cutting in a diagnosed Atrial Fibrillation (AF)
population. METHODS: The study consisted of data from the 2011 US National
Health and Wellness Survey (NHWS), a web-based survey of 75,000 patients’ de-
mographics, health care attitudes and health outcomes. Non-compliant cost cut-
ting strategies were defined as taking less medication than prescribed, cutting
tablets in half, buying fewer tablets, not filling prescriptions because of costs, not
filling prescriptions and using over-the-counter medications instead, or buying
prescriptions less often. Compliant strategies were defined as asking for generic
alternatives, asking for samples, buying prescriptions multiple months at a time
through mail order, using coupons, and using a discount card. Generalized linear
regression models were used to determine the burden of engaging in non-compli-
ant strategies on WPAI, controlling for demographics, health history, insurance
status, and comorbidities. RESULTS: Out of 1,046 diagnosed AF patients taking a
prescription medication for AF, 19.8% reported using non-compliant cost cutting
strategies, 41.3% reported using compliant strategies only, and 38.9% reported not
using any cost cutting strategies. After controlling for demographics, health his-
tory, and comorbid conditions, among the employed respondents, non-compliant
patients reported greater presenteeism (28.4%) and overall work productivity loss
(29.9%) comparedwith patientswho practice only compliant cost cutting strategies
(11.8% vs. 12.8%, respectively, p0.03 for both) . Non-compliant patients reported
significantly more activity impairment (45.4% vs. 37.5%, p0.003) before adjust-
ments, but after adjustments, no differences were found. CONCLUSIONS: In AF
patients, participating in non-compliant cost cutting strategies was found to be
associated with greater presenteeism and overall work productivity loss. These
patients should be identified and guided to improve compliance to their prescrip-
tion medications to help avoid impairment while working.
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OBJECTIVES: To determine if there were differences between statins in terms of car-
diovascular event rate and total cost among those who initiate therapy in a large
managed carepopulation.METHODS: Pharmacy andmedical claims datawere used
from 14 geographically diverse health plans in the US covering approximately 14
million members. Members had at least one pharmacy claim for atorvastatin, ro-
suvastatin, simvastatin, simvastatin/ezetimibe, pravastatin, or lovastatin during
the period between January 1, 2007 and December 31, 2008. Members who initiated
therapywere followed for 36months. Patientswere stratified into either primary or
secondary prevention. Outcomes included cardiovascular event rate and total ad-
justed cost. Multiple regression models were used to examine the association be-
tween statin therapy and cardiovascular event rate or healthcare cost while con-
trolling for demographics and observable clinical characteristics. RESULTS: A total
of 31,224 members were included, of which 25,055 and 6,169 were identified as pri-
mary and secondary prevention, respectively. Adjusted odds ratios for cardiovascular
event rates were not significantly different among the statins in either cohort. In the
primary prevention cohort, total adjusted cost was lowest for simvastatin ($13,166),
followed by lovastatin ($13,394), pravastatin ($13,811), atorvastatin ($18,209), rosuvas-
tatin ($19,194), and simvastatin/ezetimibe ($19,254); overall p0.0001. In the second-
ary prevention cohort, total adjusted cost was lowest for simvastatin ($25,111) fol-
lowed by lovastatin ($27,246), pravastatin ($27,282), simvastatin/ezetimibe ($30,412),
atorvastatin ($30,872), and rosuvastatin ($33,295); overall p0.0001. In the primary
preventioncohort, adjustedpharmacycostwas lowest for lovastatin ($4,417), followed
by simvastatin ($4,420), pravastatin ($4,715), atorvastatin ($8,210), simvastatin/
ezetimibe ($9,204), and rosuvastatin ($9,276); overall p0.0001. Similar pharmacy cost
patterns were observed in the secondary prevention cohort. CONCLUSIONS: There
appears to be similar rates of cardiovascular events among the statins. Branded
statins were generally associated with higher total cost compared to generic st-
atins, likely driven by differences in pharmacy cost.
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OBJECTIVES: The first objective of this study was to compare the predictive ability
of theGRACERisk Prediction Index (GRPI) and theCharlsonComorbidity Index (CCI)
in determining in-patient mortality, mortality within six months of discharge, and
occurrence of a second coronary event or procedure after discharge, in patients
who were admitted to a university hospital for the treatment of acute coronary
syndrome (ACS). The second objective was to determine if combining GRPI and CCI
in prediction models improved the ability to determine the same outcomes.
METHODS: Data used for this study were obtained from a large academic health
system’s acute coronary syndrome patient registry. Registry data is abstracted
from the medical record as well as from patient self-report by a telephone fol-
low-up survey 6 to 12 months after discharge. Logistic regression/ROC was used to
derive c-statistics for CCI, GRPI, and CCI-GRPI combined predictivemodels for each
of outcomes. Likelihood ratio tests were conducted to determine the contribution
of CCI when added to predictive models using the GRPI. RESULTS: A total of 1202
patients had complete data from the index hospitalization. The GRPI model had a
higher c-statistic (0.73) versus CCI model (0.68) and similar to the combined model
(0.75) to predict in-patient death; the c-statistics formodels predicting death during
the follow-up period were similar (GRPI0.74, CCI0.77, Combined0.81); and all
were similar in predicting secondary events after discharge (GRPI0.57, CCI0.60,
Combined0.58). The Likelihood ratio analysis demonstrated that adding the CCI
to existing predictive GRPI models was beneficial primarily for predicting second-
ary events post discharge. CONCLUSIONS: The CCI modestly improves models
using GRPI to predict death after discharge for an ACS event. It is an acceptable
alternative to the GRPI in predicting death and secondary events if data to derive
the GRPI are not available.
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OBJECTIVES: While considerable progress has been made, the overall global bur-
den of disease continues to escalate. The promise of translational medicine as-
sumes matching basic science to greatest unmet need can reduce the burden of
disease. Few studies have investigated the relationship between drug development
and public health priorities; fewer still have correlated funding, development and
global burden as a systemic response to unmet need. To fill crucial evidence gaps,
we investigated the relationship between the number of drugs in development and
global burden of diseasemeasures.METHODS: Burden of disease data (DALYs, YLL,
YLD, and mortality) for the top 29 most prevalent conditions were obtained from
WHO 2004 Global Burden of Disease Project. Data on drugs in development were
obtained from Adis R&D Insights (Adis International Limited). Our a priori hypoth-
esis was no relationship between the number of drugs in development (2011) and
2004 GBD metrics. Predictor and outcomes variables were log-transformed to re-
duce positive skew; following univariate linear regression analysis all measure of
burden of disease or public interest whose p0.05 were included in a stepwise
multivariate regression model. RESULTS: Univariate linear regressions demon-
strated nomeasures of current GBD (DALYs, YLL, YLD, mortality; p 0.31, 0.66, 0.2,
0.15 respectively) correlated with the current drug development pipeline. Further,
we found no correlation between future DALY projections (2008, 2015, and 2030)
and global pipeline (p  0.2, 0.26, 0.33). CONCLUSIONS: Data suggest that global
R&Dpipeline is not optimally poised to reduce current or future burden. The lack of
correlation demonstrates the need for a better metric to guide healthcare resource
allocation. We propose a “public health index” that incorporates public health
variables such as the number of available interventions, economic impact, adher-
ence, education and prevention to prioritize disease areas for drug development
targeted to maximum public health impact.
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OBJECTIVES: The illicit production of methamphetamine from the precursor
chemical pseudoephedrine (PSE) in clandestine laboratories fuels a significant por-
tion of the domestic methamphetamine supply. Although states and the federal
government have taken steps to control access to PSE, it continues to be available
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